Sugi Predict

Sugi Predict / Targets / SLC30A5

SLC30A5

Proton-coupled zinc antiporter SLC30A5 · Q8TAD4 · SLC30A5 on Sugi Atlas →

0 patent compounds predicted against SLC30A5, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SLC30A5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes PHASE4COMPLETED
Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies PHASE4COMPLETED
Supplementation With Lactoferrin in Preterm Newborns PHASE4COMPLETED
Enteral Zinc Supplementation in Very Low Birth Weight Infants PHASE3NOT_YET_RECRUITING
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children PHASE1/PHASE2COMPLETED
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer PHASE1/PHASE2COMPLETED
A Study to Assess the Effect of Itraconazole Capsules on the Pharmacokinetics of ZX-7101A Tablets in Healthy Adult Subjects in China PHASE1COMPLETED
A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes PHASE1COMPLETED
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism EARLY_PHASE1UNKNOWN
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes nanCOMPLETED
Determination of Pre-Absorptive Dissociation of Zinc From a Zinc Amino Acid Complex in Healthy Men nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Zinc and Diabetes in Patients With Thalassemia: a Pilot Study nanCOMPLETED
Role of the ATP7A Transporter in Ovarian Cancer nanCOMPLETED
Zinc Sulfate Acceptability nanCOMPLETED
Gene Expression in Inflammatory Bowel Disease nanENROLLING_BY_INVITATION
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features nanUNKNOWN
Zn Supplementation in HIV Immunological Non Responders nanRECRUITING
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) nanCOMPLETED
Exchangeable Zinc Pool Size and Zn Absorption From Sprinkles and Traditional Foods in Pakistani Infants /Toddlers nanCOMPLETED
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
Serum Zinc and Serum Magnesium in Chronic Liver Disease Patients nanCOMPLETED
Impact of Consumption of Orange-fleshed Sweet Potatoes on the Vitamin A Status of Bangladeshi Women of Reproductive Age nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Copper Supplementation in Cirrhosis nanRECRUITING
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Effects of EED on Zn Absorption and Retention in Children From a MNP nanCOMPLETED
Newborn Screening for Genetic Susceptibility to Type 1 Diabetes and Celiac Disease and Prospective Follow-up Study nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC30A5 binder may also engage these)

ProteinNameSimilarity
Q5ZLF4 — 1.000 Q5ZLF4 →
Q28CE7 — 1.000 Q28CE7 →
Q8R4H9 — 1.000 Q8R4H9 →
Q6DG36 — 0.999 Q6DG36 →
Q90X48 — 0.977 Q90X48 →
Q6DCG9 — 0.971 Q6DCG9 →
Q52KD7 — 0.971 Q52KD7 →
Q9ZUU9 — 0.970 Q9ZUU9 →
Q6NRI1 — 0.970 Q6NRI1 →
Q5BJM8 — 0.970 Q5BJM8 →
Q7Z3F1 — 0.969 Q7Z3F1 →
Q5R9A7 — 0.969 Q5R9A7 →
O14863 — 0.969 O14863 →
Q5R4D7 — 0.969 Q5R4D7 →
Q9TTF3 — 0.968 Q9TTF3 →
A4IFD7 — 0.968 A4IFD7 →
Q9M647 — 0.968 Q9M647 →
Q5MNV6 — 0.967 Q5MNV6 →
Q9UMX9 — 0.967 Q9UMX9 →
Q6UWJ1 — 0.967 Q6UWJ1 →
O35149 — 0.967 O35149 →
Q9JKN1 — 0.966 Q9JKN1 →
SLC30A7 Zinc transporter 7 0.966 landscape →
A6QPI1 — 0.966 A6QPI1 →
Q9BY10 — 0.966 Q9BY10 →
X1WEM4 — 0.966 X1WEM4 →
Q9M2G7 — 0.966 Q9M2G7 →
Q8S8S2 — 0.965 Q8S8S2 →
Q60603 — 0.965 Q60603 →
KCNMA1 Calcium-activated potassium channel subunit alpha-1 0.965 landscape →